SML1586

Oritavancin diphosphate

Name: Oritavancin diphosphate
Brand: SIGMA

98.0% ~ 102.0% (HPLC)

别名:

LY333328 diphosphate, (4"R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3"-[(4′-chloro[l,1′-biphenyl]-4-yl)methyl]vancomycin diphosphate, LY-333328

登录查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:

C₈₆H₉₇Cl₃N₁₀O₂₆ · 2H₃PO₄

化学文摘社编号:

192564-14-0

分子量:

1989.09

UNSPSC Code:

12352200

NACRES:

NA.77

主要文件

查看所有文档

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

产品名称

Oritavancin diphosphate, 98-102% (HPLC)

SMILES string

[P](=O)(O)(O)O.[P](=O)(O)(O)O.Clc1ccc(cc1)c2ccc(cc2)CN[C@@]3([C@H]([C@@H](O[C@H](C3)O[C@H]4[C@@H](O[C@@H]([C@H]([C@@H]4O)O)CO)Oc5c6cc7cc5Oc8c(cc(cc8)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]7C(=O)N[C@@H]9c%10cc(c(cc%10)O)c%11c(cc(cc%11O)O)[C@H](NC(=O)[C@@H](NC9

InChI

1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1

InChI key

PWTROOMOPLCZHB-BHYQHFGMSA-N

assay

98-102% (HPLC)

form

powder

color

white to off-white

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and organisms resistant to vancomycin and other antibiotics such as linezolid and daptomycin. Oritavancin has multiple mechanisms of action, including inhibition of transglycosylation, inhibition of transpeptidation, and cell membrane interaction/disruption. Oritavancin also has a long half-life, allowing for a single intravenous dose of rather than the standard vacomycin treatment of twice-daily infusions for ten days.

Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens.